연구성과로 돌아가기
2021 연구성과 (170 / 281)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Review | Effectiveness of pharmacologic treatment for dysphagia in Parkinson's disease: a narrative review | Background The effectiveness of pharmacological treatment on dysphagia in Parkinson's disease (PD) is debatable. We reviewed the literature for analyzing the effect of pharmacological treatment on the improvement of dysphagia in PD patients. Methods We searched the PubMed database for papers published before June 21, 2020, that evaluated the effect of pharmacologic treatments for improving dysphagia in patients with PD. The following inclusion criteria were applied for the selection of articles: 1) studies performed on patients with dysphagia due to PD, 2) studies where pharmacologic treatment was applied for improvement of dysphagia, and 3) those where follow-up evaluation was performed after the treatment. Results The primary literature search yielded 415 relevant papers. After reading their titles and abstracts and assessing their eligibility based on the full-text articles, we finally included nine studies in this review. In five previous studies, the positive effects of dopaminergic drugs on dysphagia were reported, whereas two showed no significant positive results. The remaining two studies showed equivocal results. Conclusion We found that dopaminergic drugs have some potential to improve dysphagia in patients with PD. However, studies with high-quality evidence are lacking. For the clear elucidation of the effect of dopaminergic drugs on dysphagia in patients with PD, randomized controlled trials with large cohorts and detailed analyses should be conducted in the future. | Chang, Min Cheol; Park, Jin-Sung; Lee, Byung Joo; Park, Donghwi | Yeungnam Univ, Coll Med, Dept Rehabil Med, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Daegu Fatima Hosp, Dept Rehabil Med, Daegu, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Phys Med & Rehabil, 877 Bangeojinsunghwndo Ro, Ulsan 44033, South Korea | ; Park, Donghwi/GYQ-6185-2022; Chang, Min Cheol/AAE-2321-2022 | 23767019400; 44061744500; 57202436497; 56606561400 | bdome@hanmail.net; | NEUROLOGICAL SCIENCES | NEUROL SCI | 1590-1874 | 1590-3478 | 42 | 2 | SCIE | CLINICAL NEUROLOGY;NEUROSCIENCES | 2021 | 3.83 | 46.5 | 0.65 | 2025-07-30 | 15 | 13 | Parkinson disease; Dysphagia; Pharmacological treatment; Dopaminergic drug | OROPHARYNGEAL DYSPHAGIA; STIMULATION; DYSFUNCTION; PREVALENCE; THERAPY | Dopaminergic drug; Dysphagia; Parkinson disease; Pharmacological treatment | Deglutition Disorders; Humans; Parkinson Disease; apomorphine; benserazide; carbidopa; domperidone; levodopa; placebo; controlled study; dysphagia; follow up; human; Parkinson disease; Review; statistically significant result; complication; dysphagia | English | 2021 | 2021-02 | 10.1007/s10072-020-04865-w | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Air-interface virtualization using filter bank multicarrier and orthogonal frequency division multiplexing configurations | Mobile networks have to cater for diverse services that have distinct requirements in terms of bandwidth, latency, and so on. Network virtualization is a key technology that efficiently utilizes the network resources to meet these service requirements. In this work, we investigate radio virtualization for creating fine-grained network slices using orthogonal frequency division multiplexing (OFDM) and filter bank multicarrier (FBMC) combinations; the two are individually referred to as virtual radios (VRs). Using universal software radio peripherals (USRPs), we experimentally analyze multiple configurations of VRs including OFDM-OFDM, OFDM-FBMC, and FBMC-FBMC. An extensive performance comparison is done on the basis of error rate, spectral efficiency, interference power, and computational complexity of the VR configurations that are confined within an operational bandwidth. An increase in transmit power of the VRs is theoretically expected to decrease the error rate, but there is also an increase in adjacent channel interference. Therefore, after a certain decrease in error rate with increase in transmit power, an inflection point is reached after which the error rate starts to increase. Of the three combinations, FBMC-FBMC gives the lowest error rate (at the highest transmit power), that is,10%and18%lower than OFDM-FBMC and OFDM-OFDM, respectively. However, FBMC-FBMC also has the highest complexity. We conclude that this air-interface virtualization framework allows the network to use the waveform configuration that is best suited to a particular set of services, while considering the pros and cons of the individual waveforms. | Saad, Malik Muhammad; Bhatti, Farrukh Aziz; Zafar, Adnan; Jangsher, Sobia; Kim, Dongkyun; Maqsood, Moazam | Inst Space Technol, Dept Elect Engn, WiSP Lab, Islamabad 44000, Pakistan; Kyungpook Natl Univ, Sch Comp Sci & Engn, Daegu 41566, South Korea | Saad, Malik/ABF-9433-2021; جانجشير, سوبيا/GNO-9440-2022; Zafar, Adnan/AAL-8238-2020 | 57220715290; 55074405200; 26326034300; 48861413200; 35753648800; 36668920100 | farrukh.aziz@ist.edu.pk;dongkyun@knu.ac.kr; | TRANSACTIONS ON EMERGING TELECOMMUNICATIONS TECHNOLOGIES | T EMERG TELECOMMUN T | 2161-3915 | 32 | 2 | SCIE | TELECOMMUNICATIONS | 2021 | 3.31 | 46.8 | 0.28 | 2025-07-30 | 4 | 4 | CORE NETWORK | Bandwidth; Complex networks; Errors; Filter banks; Software radio; Virtualization; Adjacent channel interference; Filter-bank multicarrier; Multiple configurations; Network virtualization; Operational bandwidth; Performance comparison; Service requirements; Spectral efficiencies; Orthogonal frequency division multiplexing | English | 2021 | 2021-02 | 10.1002/ett.4154 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn's Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage | Background/Aims: We evaluated whether anti-Saccharomyces cerevisiae antibody (ASCA) titers are associated with diagnostic findings, disease activity, Paris classification phenotypes, and persistence after infliximab (IFX) treatment in children with Crohn's disease (CD). We also investigated the role of ASCA as a predictor of mucosal healing (MH) and clinical remission (CR). Methods: This study included 61 CD patients aged 19 years or younger who were diagnosed and treated between September 2010 and January 2019 and followed for at least 1 year. ASCA was regularly measured at the diagnosis of CD and at least 1 year after IFX therapy. Results: The average follow-up period was 3.8 +/- 3.4 years (range, 1.0 to 7.2 years). Regression analysis showed that the ASCA titer was the only factor associated with Simple Endoscopic Score for Crohn's Disease (SES-CD) or CR among all the parameters. In patients who had achieved MH (SES-CD=0), ASCA immunoglobulin G (IgG) was not associated with MH, but in patients without MH, ASCA IgG was associated with SES-CD (p=0.005) and CR (p<0.001). The cutoff value of ASCA IgG in patients with CR was 21.8 units. However, there was no difference in the relapse rate between the ASCA IgG-positive and-negative groups during the follow-up period. Conclusions: In patients who have not achieved MH, ASCA IgG is closely related to mucosal damage and CR. Unlike Western studies, ASCA IgG may be more helpful in predicting prognosis than immunoglobulin A in Korean patients, but it is not an appropriate indicator to predict the relapse of CD. (Gut Liver 2021;15:763-770) | Kim, Mi Jin; Kim, Eunsil; Kang, Ben; Lee, Yoon; Kang, Eun-Suk; Choe, Yon Ho | Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu, South Korea; Korea Univ, Anam Hosp, Coll Med, Dept Pediat, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med & Genet, Seoul, South Korea | ; Kim, Mi Jin/GXH-9639-2022; 康, 奔/JMQ-0812-2023 | 56638815200; 57205500267; 57194823199; 55588945800; 20234715300; 21333712100 | i101016@skku.edu; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 5 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0.54 | 2025-07-30 | 5 | 7 | Crohn disease; Anti-Saccharomyces cerevisiae; Children; Marker; Mucosal healing | INFLAMMATORY-BOWEL-DISEASE; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; DIAGNOSIS; CHILDREN; ASCA; SURGERY; UTILITY; RISK | Anti-Saccharomyces cerevisiae; Children; Crohn disease; Marker; Mucosal healing | Antibodies, Fungal; Crohn Disease; Humans; Immunoglobulin A; Infliximab; azathioprine; corticosteroid; fungus antibody; immunoglobulin G; infliximab; Saccharomyces cerevisiae antibody; unclassified drug; fungus antibody; immunoglobulin A; adolescent; antibody titer; Article; controlled study; Crohn disease; diagnostic accuracy; diagnostic test accuracy study; diagnostic value; digestive system disease assessment; disease activity; female; follow up; healing; human; major clinical study; male; mucosal disease; mucosal healing; Paris classification; pediatric patient; phenotype; prediction; prognosis; receiver operating characteristic; regression analysis; remission; Saccharomyces cerevisiae; sensitivity and specificity; Simple Endoscopic Score for Crohn Disease; Crohn disease | English | 2021 | 2021-09 | 10.5009/gnl20212 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Review | Clinical and Technical Guideline for Endoscopic Ultrasound (EUS)-Guided Tissue Acquisition of Pancreatic Solid Tumor: Korean Society of Gastrointestinal Endoscopy (KSGE) | Endoscopic ultrasound (EUS)-guided tissue acquisition of pancreatic solid tumor requires a strict recommendation for its proper use in clinical practice because of its technical difficulty and invasiveness. The Korean Society of Gastrointestinal Endoscopy (KSGE) appointed a task force to draft clinical practice guidelines for EUS-guided tissue acquisition of pancreatic solid tumor. The strength of recommendation and the level of evidence for each statement were graded according to the Minds Handbook for Clinical Practice Guideline Development 2014. The committee, comprising a development panel of 16 endosonographers and an expert on guideline development methodology, developed 12 evidence-based recommendations in eight categories intended to help physicians make evidence-based clinical judgments with regard to the diagnosis of pancreatic solid tumor. This clinical practice guideline discusses EUS-guided sampling in pancreatic solid tumor and makes recommendations on circumstances that warrant its use, technical issues related to maximizing the diagnostic yield (e.g., needle type, needle diameter, adequate number of needle passes, sample obtaining techniques, and methods of specimen processing), adverse events of EUS-guided tissue acquisition, and learning-related issues. This guideline was reviewed by external experts and suggests best practices recommended based on the evidence available at the time of preparation. This guideline may not be applicable for all clinical situations and should be interpreted in light of specific situations and the availability of resources. It will be revised as necessary to cover progress and changes in technology and evidence from clinical practice. | Chung, Moon Jae; Park, Se Woo; Kim, Seong-Hun; Cho, Chang Min; Choi, Jun-Ho; Choi, Eun Kwang; Lee, Tae Hoon; Cho, Eunae; Lee, Jun Kyu; Song, Tae Jun; Lee, Jae Min; Son, Jun Hyuk; Park, Jin Suk; Oh, Chi Hyuk; Park, Dong-Ah; Byeon, Jeong-Sik; Lee, Soo Teik; Kim, Ho Gak; Chun, Hoon Jai; Choi, Ho Soon; Park, Chan Guk; Cho, Joo Young | Yonsei Univ, Severance Hosp, Dept Internal Med, Div Gastroenterol,Coll Med, Seoul, South Korea; Hallym Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Hwaseong, South Korea; Jeonbuk Natl Univ, Biomed Res Inst, Jeonbuk Natl Univ Hosp, Dept Internal Med,Res Inst Clin Med, Jeonju, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Dankook Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Cheonan, South Korea; Jeju Natl Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Jeju, South Korea; Soonchunhyang Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Cheonan, South Korea; Chonnam Natl Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Gwangju, South Korea; Dongguk Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Goyang, South Korea; Ulsan Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea; Korea Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea; Inje Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Busan, South Korea; Inha Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Incheon, South Korea; Kyung Hee Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea; Natl Evidence Based Healthcare Collaborating Agcy, Div Healthcare Technol Assessment Res, Off Hlth Technol Assessment Res, Seoul, South Korea; Daegu Catholic Univ, Dept Internal Med, Div Gastroenterol, Sch Med, Daegu, South Korea; Hanyang Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seoul, South Korea; Chosun Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Gwangju, South Korea; Cha Univ, Dept Internal Med, Div Gastroenterol, Coll Med, Seongnam, South Korea | Lee, Tae/B-1160-2013; Song, Taejun/JVZ-2733-2024; CHO, JOO/AAJ-2012-2020; Lee, Si/ABH-1408-2020; Lee, Kyoungbun/F-6358-2011; Kim, Seok-Hwan/G-9981-2015 | 8398208000; 57145012800; 57206878084; 57158287600; 55661671700; 25930823000; 16506642900; 57225705236; 57201264381; 26028951400; 8636426500; 55711096600; 57223103388; 57216574104; 55857456800; 7004081013; 7601418502; 7410139763; 7202215162; 7404339634; 7408415189; 57216358471 | britnepak@hallym.or.kr; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 3 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0.63 | 2025-07-30 | 15 | 15 | Endoscopic ultrasound; Pancreatic solid tumor; Tissue; Technique; Guideline | FINE-NEEDLE-ASPIRATION; GASTROENTEROLOGY EUROPEAN-SOCIETY; ON-SITE EVALUATION; EUS-FNA SPECIMENS; SUCTION TECHNIQUES; PREDICTS SURVIVAL; DIAGNOSTIC YIELD; ADVERSE EVENTS; LEARNING-CURVE; MESSENGER-RNA | Endoscopic ultrasound; Guideline; Pancreatic solid tumor; Technique; Tissue | Endoscopy, Gastrointestinal; Endosonography; Humans; Pancreas; Pancreatic Neoplasms; Republic of Korea; abdominal pain; bile leakage; bleeding; cancer prognosis; chemosensitivity; clinical practice; cytology; diagnostic accuracy; diagnostic value; distal pancreatectomy; endoscopic ultrasonography; evidence based medicine; fever; fine needle aspiration biopsy; histopathology; human; immunohistochemistry; infection; Korea; medical decision making; medical expert; medical society; methodology; pancreas cancer; pancreas cyst; pancreas tumor; pancreatitis; perforation; practice guideline; prediction; Review; sonographer; technology; telemedicine; treatment planning; tumor seeding; diagnostic imaging; gastrointestinal endoscopy; pancreas; pancreas tumor; South Korea | English | 2021 | 2021-05 | 10.5009/gnl20302 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Clinical Outcomes of Endoscopic Resection for Low-Grade Dysplasia and High-Grade Dysplasia on Gastric Pretreatment Biopsy: Korea ESD Study Group | Background/Aims: Some cases of gastric low-grade dysplasia (LGD) and high-grade dysplasia (HGD) on forceps biopsy (FB) are diagnosed as gastric cancer (GC) after endoscopic resection (ER). This study aims to evaluate the clinical outcomes of ER for gastric LGD and HGD on pretreatment FB and to identify the factors that predict pathologic upstaging to GC. Methods: Patients who underwent ER for LGD and HGD on pretreatment FB from March 2005 to February 2018 in 14 hospitals in South Korea were enrolled, and the patients' medical records were reviewed retrospectively. Results: This study included 2,150 cases of LGD and 1,534 cases of HGD diagnosed by pretreatment FB. In total, 589 of 2,150 LGDs (27.4%) were diagnosed as GC after ER. Helicobacter pylori infection, smoking history, tumor location in the lower third of the stomach, tumor size >10 mm, depressed lesion, and ulceration significantly predicted GC. A total of 1,115 out of 1,534 HGDs (72.7%) were diagnosed with GC after ER. Previous history of GC, H. pylori infection, smoking history, tumor location in the lower third of the stomach, tumor size >10 mm, depressed lesion, and ulceration were significantly associated with GC. As the number of risk factors predicting GC increased in both LGD and HGD on pretreatment FB, the rate of upstaging to GC after ER increased. Conclusions: A substantial proportion of LGDs and HGDs on pretreatment FB were diagnosed as GC after ER. Accurate ER procedures such as endoscopic submucosal dissection should be recommended in cases of LGD and HGD with factors predicting pathologic upstaging to GC. | Jeon, Jung Won; Kim, Soo Jin; Jang, Jae Young; Kim, Sun-Moon; Lim, Chul-Hyun; Park, Jae Myung; Hong, Su Jin; Kim, Chan Gyoo; Jeon, Seong Woo; Lee, Si Hyung; Sung, Jae Kyu; Baik, Gwang Ho | Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Internal Med, Seoul, South Korea; Kyung Hee Univ Hosp Gangdong, Inst Med Sci, Seoul, South Korea; Kyung Hee Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Konyang Univ, Coll Med, Dept Internal Med, Daejeon, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea; Soonchunhyang Univ, Coll Med, Dept Internal Med, Bucheon, South Korea; Natl Canc Ctr, Res Inst & Hosp, Ctr Gastr Canc, Goyang, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea; Chungnam Natl Univ, Sch Med, Dept Internal Med, Daejeon, South Korea; Hallym Univ, Chuncheon Sacred Heart Hosp, Coll Med, Dept Internal Med, Chunchon, South Korea; Hallym Univ, Coll Med, Inst Liver & Digest Dis, Chunchon, South Korea | Lee, Si/ABH-1408-2020; Park, Jae Myung/AGK-6655-2022; Jang, Jae/AAN-1508-2020; Jeon, Seongwoo/AAU-4618-2020; Kim, Soo Jin/HKV-1826-2023 | 57215598164; 57208619913; 57215881098; 57206877980; 36056837600; 8548758100; 35285527200; 57218674652; 9733636500; 35771122400; 8439931900; 7801423477 | baikgh@hallym.or.kr; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 2 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0.92 | 2025-07-30 | 15 | 16 | Low-grade dysplasia; High-grade dysplasia; Endoscopic resection; Gastric cancer; Risk factors | FORCEPS BIOPSY; EPITHELIAL NEOPLASIA; SUBMUCOSAL DISSECTION; LESIONS; DISCREPANCY; CARCINOMA; CRITERIA; RISK | Endoscopic resection; Gastric cancer; High-grade dysplasia; Low-grade dysplasia; Risk factors | Biopsy; Helicobacter Infections; Helicobacter pylori; Humans; Precancerous Conditions; Republic of Korea; Retrospective Studies; Stomach; Stomach Neoplasms; adult; aged; Article; cancer staging; clinical evaluation; clinical outcome; disease classification; endoscopic surgery; female; gastrointestinal dysplasia; Helicobacter infection; human; human tissue; major clinical study; male; medical record review; middle aged; prediction; retrospective study; risk factor; smoking; South Korea; stomach biopsy; stomach cancer; stomach ulcer; tumor volume; biopsy; Helicobacter infection; Helicobacter pylori; precancer; stomach; stomach tumor | English | 2021 | 2021-03 | 10.5009/gnl19275 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Difficult Biliary Cannulation from the Perspective of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Identifying the Optimal Timing for the Rescue Cannulation Technique | Background/Aims: Recently, the European Society of Gastrointestinal Endoscopy (ESGE) proposed criteria for "difficult biliary cannulation" during endoscopic retrograde cholangiopancreatography (ERCP). This study aimed to investigate the clinical relevance of the ESGE criteria from the perspective of post-ERCP pancreatitis (PEP). Methods: An ERCP database was prospectively maintained between November 2014 and December 2015 across six teaching hospitals in South Korea. The ESGE criteria (biliary cannulation time, the number of cannulation attempts, and inadvertent pancreatic duct [PD] manipulation) were recorded in this database as well as other technical factors. Logistic regression analysis was used to identify risk factors for PEP. Then, the PEP prediction model was investigated using decision tree analysis. Results: We analyzed 1,067 consecutive patients with naive papilla. The overall rate of PEP was 6.6%. Multivariate analysis revealed that female sex (odds ratio [OR], 1.860; 95% confidence interval [CI], 1.124 to 3.078), a selective biliary cannulation duration >5 minutes (OR, 3.282; 95% CI, 1.641 to 6.566), and inadvertent PD manipulation (OR, 2.614; 95% CI, 1.480 to 4.617) were significant factors affecting PEP. Decision tree analysis revealed that biliary cannulation time (chi(2)=49.857, p5 minutes, and >5 minutes with inadvertent PD manipulation, respectively. Conclusions: Biliary cannulation time and inadvertent PD manipulation could be relevant indicators of PEP, and 5 minutes might be used as a cutoff value for the implementation of the rescue cannulation technique. | Lee, Yoon Suk; Cho, Chang Min; Cho, Kwang Bum; Heo, Jun; Jung, Min Kyu; Kim, Sung Bum; Kim, Kook Hyun; Kim, Tae Nyeun; Lee, Dong Wook; Han, Jimin; Kim, Ho Gak; Kim, Daejin; Kim, Hyunsoo | Inje Univ, Dept Internal Med, Coll Med, Goyang, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea; Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; Daegu Catholic Univ, Dept Internal Med, Sch Med, Daegu, South Korea; Daegu Fatima Hosp, Dept Internal Med, Daegu, South Korea | ; Han, Jimin/AAC-5497-2022; Kim, Min/ACN-6827-2022; Kim, Sung/I-2997-2017; LEE, Yoon-Suk/D-1827-2019; Lee, Yoon Suk/D-1827-2019; Kim, Seok-Hwan/G-9981-2015 | 57219432560; 57158287600; 7403956834; 36448170600; 56783168100; 36619660100; 37094434600; 8449938100; 57202974895; 8694531200; 7410139763; 57214770550; 57210863621 | cmcho@knu.ac.kr; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 3 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 1 | 2025-07-30 | 25 | 17 | Pancreatitis; Cholangiopancreatography, endoscopic retrograde; Risk factors; Decision trees; Practice guideline | EARLY PRECUT SPHINCTEROTOMY; ERCP PANCREATITIS; EUROPEAN-SOCIETY; RISK-FACTORS; REGRESSION; CLASSIFICATION; COMPLICATIONS; ACCESS | Cholangiopancreatography, endoscopic retrograde; Decision trees; Pancreatitis; Practice guideline; Risk factors | Catheterization; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Female; Humans; Pancreatic Ducts; Pancreatitis; Risk Factors; adult; aged; Article; biliary cannulation; confidence interval; controlled study; decision tree; endoscopic retrograde cholangiopancreatography; female; human; implementation science; logistic regression analysis; major clinical study; male; multivariate analysis; odds ratio; operation duration; pancreatic duct; pancreatitis; practice guideline; prediction; prospective study; risk assessment; risk factor; sex; South Korea; South Korean; adverse event; catheterization; common bile duct; pancreatitis | English | 2021 | 2021-05 | 10.5009/gnl19304 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study | Background/Aims: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta (R) (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta (R) thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta (R), n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta (R), n=215). The posttreatment assessments included the primary (erosion im-provement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of red-ness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated. Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta (R)-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta (R)- treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was -4.01% (95% confidence interval [CI], -13.09% to 5.06%) in the ITT analysis and -4.44% (95% CI, -13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta (R)-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates. Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta (R)) thrice daily. Both formulations showed a similar efficacy in treat-ing erosive gastritis. (Gut Liver, Published online April 7, 2021) | Kim, Gwang Ha; Lee, Hang Lak; Joo, Moon Kyung; Park, Hong Jun; Jung, Sung Woo; Lee, Ok-Jae; Kim, Hyungkil; Chun, Hoon Jai; Lee, Soo Teik; Kim, Ji Won; Jeon, Han Ho; Chung, Il-Kwun; Kim, Hyun-Soo; Lee, Dong Ho; Kim, Kyoung-Oh; Lim, Yun Jeong; Park, Seun-Ja; Cho, Soo-Jeong; Kim, Byung-Wook; Ko, Kwang Hyun; Jeon, Seong Woo; Kim, Jae Gyu; Sung, In-Kyung; Kim, Tae Nyeun; Sung, Jae Kyu; Park, Jong-Jae | Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; Hanyang Univ Hosp, Dept Internal Med, Seoul, South Korea; Korea Univ, Dept Internal Med, Div Gastroenterol, Guro Hosp, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Wonju Coll Med, Wonju, South Korea; Korea Univ, Dept Internal Med, Div Gastroenterol, Ansan Hosp, Ansan, South Korea; Gyeongsang Natl Univ, Dept Internal Med, Coll Med, Jinju, South Korea; Inha Univ, Dept Internal Med, Sch Med, Incheon, South Korea; Korea Univ, Inst Gastrointestinal Med Instrument Res, Dept Internal Med, Div Gastroenterol & Hepatol,Coll Med, Seoul, South Korea; Jeonbuk Natl Univ Hosp, Dept Internal Med, Jeonju, South Korea; Seoul Natl Univ, SMG SNU Boramae Med Ctr, Dept Internal Med, Coll Med, Seoul, South Korea; Ilsan Hosp, Dept Internal Med, Natl Hlth Insurance Serv, Goyang, South Korea; Soonchunhyang Univ, Dept Internal Med, Coll Med, Cheonan, South Korea; Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Gwangju, South Korea; Gachon Univ, Dept Internal Med, Gil Med Ctr, Incheon, South Korea; Dongguk Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Kosin Univ, Coll Med, Dept Internal Med, Gospel Hosp, Busan, South Korea; Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Incheon St Marys Hosp, Seoul, South Korea; CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Seongnam, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Chung Ang Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Konkuk Univ, Dept Internal Med, Sch Med, Seoul, South Korea; Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; Chungnam Natl Univ, Dept Internal Med, Coll Med, Daejeon, South Korea | Kim, Jung/D-3112-2015; Kim, Woo/D-2733-2015; Kim, Gwang Ha/ABF-3932-2021; Lee, Dong-Ho/J-5576-2012; Lee, Si/ABH-1408-2020; Kim, Min/ACN-6827-2022; Jeon, Seongwoo/AAU-4618-2020; Kim, Jung/L-9791-2019 | 35214772400; 57219409756; 35313509000; 57096148200; 35174493300; 8569374900; 57941472200; 7202215162; 7601418502; 57204539255; 57193735926; 59436748700; 57210863499; 55568531099; 12778286500; 56501161800; 57206639713; 7404884438; 57216356690; 35327264300; 9733636500; 57486236700; 57226383709; 8449938100; 8439931900; 34668368400 | gi7pjj@korea.ac.kr; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 6 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 1.07 | 2025-07-30 | 10 | 15 | Adverse drug reaction; Gastritis; Intention-to-treat analysis; Phase III clinical trial; Rebamipide | HELICOBACTER-PYLORI; MECHANISMS; DA-9601; RISK | Adverse drug reaction; Gastritis; Intention-to-treat analysis; Phase III clinical trial; Rebamipide | Alanine; Double-Blind Method; Gastritis; Humans; Quinolones; Stomach Ulcer; Treatment Outcome; ad 203; gastrointestinal agent; rebamipide; unclassified drug; alanine; quinolone derivative; rebamipide; adult; aged; Article; controlled study; disease severity; dizziness; double blind procedure; drug efficacy; drug safety; drug withdrawal; edema; erosive gastritis; female; follow up; gastric redness; human; intention to treat analysis; major clinical study; male; middle aged; multicenter study; patient compliance; phase 3 clinical trial; randomized controlled trial; stomach disease; stomach erosion; stomach hemorrhage; treatment duration; clinical trial; gastritis; stomach ulcer; treatment outcome | English | 2021 | 2021-11 | 10.5009/gnl20338 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Review | Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020 | Helicobacter pylori infection is one of the most common infectious diseases worldwide. Although the prevalence of H. pylori is gradually decreasing, approximately half of the world's population still becomes infected with this disease. H. pylori is responsible for substantial gastrointestinal morbidity worldwide, with a high disease burden. It is the most common cause of gastric and duodenal ulcers and gastric cancer. Since the revision of the H. pylori clinical practice guidelines in 2013 in Korea, the eradication rate of H. pylori has gradually decreased with the use of a clarithromycin-based triple therapy for 7 days. According to a nationwide randomized controlled study conducted by the Korean College of Helicobacter and Upper Gastrointestinal Research released in 2018, the intention-to-treat eradication rate was only 63.9%, which was mostly due to increased antimicrobial resistance, especially from clarithromycin. The clinical practice guidelines for the treatment of H. pylori were updated according to evidence-based medicine from a meta-analysis conducted on a target group receiving the latest level of eradication therapy. The draft recommendations developed based on the meta-analysis were finalized after an expert consensus on three recommendations regarding the indication for treatment and eight recommendations for the treatment itself. These guidelines were designed to provide clinical evidence for the treatment (including primary care treatment) of H. pylori infection to patients, nurses, medical school students, policymakers, and clinicians. These may differ from current medical insurance standards and will be revised if more evidence emerges in the future. | Jung, Hye-Kyung; Kang, Seung Joo; Lee, Yong Chan; Yang, Hyo-Joon; Park, Seon-Young; Shin, Cheol Min; Kim, Sung Eun; Lim, Hyun Chul; Kim, Jie-Hyun; Nam, Su Youn; Shin, Woon Geon; Park, Jae Myung; Choi, Il Ju; Kim, Jae Gyu; Choi, Miyoung | Ewha Womans Univ, Dept Internal Med, Sch Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Gangnam Ctr, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Gastroenterol,Sch Med, Seoul, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Gastrointestinal Canc Ctr, Sch Med, Seoul, South Korea; Chonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, South Korea; Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; Kosin Univ, Dept Internal Med, Coll Med, Busan, South Korea; Yonsei Univ, Yongin Severance Hosp, Dept Internal Med, Coll Med, Yongin, South Korea; Yonsei Univ, Inst Gastroenterol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Ctr Gastr Canc, Sch Med,Chilgok Hosp, Daegu, South Korea; Hallym Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol,Seoul St Marys Hosp, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc, Goyang, South Korea; Chung Ang Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Natl Evidence Based Healthcare Collaborating Agcy, Div Healthcare Technol Assessment Res, Seoul, South Korea | ; Choi, Miyoung/HZH-8501-2023; Kim, Jie-Hyun/Q-9061-2019; Lee, Yoojin/AAB-9799-2022; Park, Jae Myung/AGK-6655-2022; KIM, SUNG/ADF-8559-2022 | 7403029723; 51261274600; 35264717600; 57188930761; 7501833800; 35338000300; 58848142900; 36545233500; 49461401400; 55617028500; 13606883400; 8548758100; 7401471464; 34771414000; 57129603200 | leeyc@yuhs.ac; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 2 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 3.92 | 2025-07-30 | 90 | 104 | Helicobacter pylori; Guidelines; Treatment; Meta-analysis; Microbial sensitivity tests | STANDARD TRIPLE THERAPY; PROTON-PUMP INHIBITOR; RANDOMIZED CLINICAL-TRIAL; 10-DAY SEQUENTIAL THERAPY; QUADRUPLE CONCOMITANT THERAPY; DOSE DUAL THERAPY; IRON-DEFICIENCY ANEMIA; FUNCTIONAL DYSPEPSIA; RESCUE THERAPY; BISMUTH QUADRUPLE | Guidelines; Helicobacter pylori; Meta-analysis; Microbial sensitivity tests; Treatment | Clarithromycin; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Randomized Controlled Trials as Topic; Republic of Korea; amoxicillin; bismuth citrate; clarithromycin; levofloxacin; metronidazole; proton pump inhibitor; quinoline derived antiinfective agent; rabeprazole; rifabutin; tetracycline; clarithromycin; atrophic gastritis; drug megadose; dyspepsia; endoscopic surgery; eradication therapy; evidence based practice; health care personnel; health care policy; health insurance; Helicobacter infection; Helicobacter pylori; human; intestine metaplasia; Korea; medical student; meta analysis; pathogen clearance; patient preference; practice guideline; primary medical care; randomized controlled trial (topic); Review; salvage therapy; stomach adenoma; systematic review; treatment failure; treatment indication; duodenum ulcer; Helicobacter infection; Helicobacter pylori; South Korea | English | 2021 | 2021-03 | 10.5009/gnl20288 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease | Background/Aims: Anti-drug antibodies (ADAs) can develop during treatment with anti-tumor necrosis factor (TNF) agents. We aimed to investigate the factors associated with immunogenicity of anti-TNF agents in pediatric patients with inflammatory bowel disease (IBD) and observe the clinical course of ADA-positive patients. Methods: Pediatric IBD patients receiving maintenance treatment with anti-TNF agents who had been tested for ADAs against infliximab (IFX) or adalimumab (ADL) were included in this crosssectional study. Factors associated with ADA positivity were investigated by analyzing clinicodemographic, laboratory, and treatment-related factors. Results: A total of 76 patients (Crohn's disease, 65; ulcerative colitis, 11) were included. Among these, 59 and 17 patients were receiving IFX and ADL, respectively. ADAs were found in 10 patients (13.2%), all of whom were receiving IFX. According to multivariable logistic regression analysis, the IFX trough level (TL) was associated with ADA positivity (odds ratio, 0.25; 95% confidence interval [CI], 0.08 to 0.51; p=0.002). According to the receiver operating characteristic analysis, the optimal cutoff of the IFX TLs for stratifying patients based on the presence of ADAs against IFX was 1.88 mu g/mL (area under curve, 0.941; 95% CI, 0.873 to 1.000; sensitivity, 80.0%; specificity, 95.9%; p<0.001). Among the 10 patients with ADAs against IFX, five patients (50%) switched to ADL within 1 year, while five patients (50%) kept receiving IFX. Transient ADAs were observed in three patients (30%). Conclusions: IFX TL was the only factor associated with ADA formation in pediatric IBD patients receiving IFX. Future studies based on serial and proactive therapeutic drug monitoring are required in the future. | Kim, Ju Young; Lee, Yoon; Choe, Byung-Ho; Kang, Ben | Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu, South Korea; Eulji Univ, Dept Pediat, Sch Med, Daejeon, South Korea; Korea Univ, Dept Pediat, Sch Med, Seoul, South Korea; Crohns & Colitis Assoc Daegu Gyeongbuk CCAiD, Daegu, South Korea | ; Choe, Byung-Ho/KSM-6251-2024; Kim, Youngmin/C-7926-2019; 康, 奔/JMQ-0812-2023 | 57202996384; 55588945800; 57574977300; 57194823199 | benkang@knu.ac.kr; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 4 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0.23 | 2025-07-30 | 3 | 3 | Infliximab; Adalimumab; Crohn disease; Ulcerative colitis; Children | INFLIXIMAB TROUGH LEVELS; CROHNS-DISEASE; COMBINATION THERAPY; ANTIDRUG ANTIBODIES; CLINICAL-USE; DRUG; CHILDREN; PHARMACOKINETICS; REMISSION; IMPACT | Adalimumab; Children; Crohn disease; Infliximab; Ulcerative colitis | Adalimumab; Child; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Treatment Outcome; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; adalimumab; C reactive protein; calgranulin; drug antibody; immunomodulating agent; infliximab; tumor necrosis factor inhibitor; adalimumab; gastrointestinal agent; infliximab; tumor necrosis factor; tumor necrosis factor inhibitor; adolescent; anaphylaxis; Article; child; Crohn disease; cross-sectional study; drug dose intensification; drug substitution; drug withdrawal; enzyme linked immunosorbent assay; erythrocyte sedimentation rate; female; human; immunogenicity; inflammatory bowel disease; leukocyte count; maintenance therapy; major clinical study; male; minimum plasma concentration; predictive value; receiver operating characteristic; remission; retrospective study; sensitivity and specificity; ulcerative colitis; treatment outcome; ulcerative colitis | English | 2021 | 2021-07 | 10.5009/gnl20134 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Editorial Material | Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis? | See "Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis" by Yong Il Lee, et al. on page 232, Vol. 15, No. 2, 2021 | Kim, Eun Soo | Kyungpook Natl Univ, Sch Med, Div Gastroenterol, Dept Internal Med, Daegu, South Korea | ; Kim, Sang/J-5398-2012 | 57203086704 | dandy813@hanmail.net; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 2 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 2.19 | 2025-07-30 | 3 | 4 | THERAPY; NAIVE | Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Colitis, Ulcerative; Humans; Infliximab; adalimumab; infliximab; adalimumab; antiinflammatory agent; infliximab; monoclonal antibody; clinical outcome; clinical practice; disease severity; drug efficacy; drug safety; Editorial; ethnicity; hospitalization; human; incidence; patient-reported outcome; prescription; quality of life; remission; risk reduction; treatment response; ulcerative colitis | English | 2021 | 2021-03 | 10.5009/gnl210098 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Correction | Inhalation of ammonium sulfate and ammonium nitrate adversely affect sperm function (vol 96, pg 424, 2020) | Bae, Jeong-Won; Kwon, Hong Ju; Kim, So-Hye; Ma, Lei; Im, Hobin; Kim, Eungyung; Kim, Myoung Ok; Kwon, Woo-Sung | Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, Sangju 37224, Gyeongsangbuk D, South Korea; Kyungpook Natl Univ, Dept Anim Biotechnol, Sangju 37224, Gyeongsangbuk D, South Korea | Bae, Jeong-Won/AAH-4932-2021; Kwon, Woo-Sung/J-6731-2019 | 57211231093; 57217867533; 57211230697; 57217867673; 57217867362; 57217871658; 8934745900; 54383715800 | ok4325@knu.ac.kr;wskwon@knu.ac.kr; | REPRODUCTIVE TOXICOLOGY | REPROD TOXICOL | 0890-6238 | 1873-1708 | 102 | SCIE | REPRODUCTIVE BIOLOGY;TOXICOLOGY | 2021 | 3.421 | 46.8 | 2.58 | 2025-07-30 | 1 | 1 | erratum | English | 2021 | 2021-06 | 10.1016/j.reprotox.2020.12.020 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||||
| ○ | ○ | Editorial Material | Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis? | See "Clinical Characteristics and Long-term Prognosis of Elderly-Onset Ulcerative Colitis in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea" by Sang Hyoung Park, et al. on page 742, Vol. 15, No. 5, 2021 | Lee, Jin Wook; Kim, Eun Soo | Keimyung Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Daegu, South Korea | ; Kim, Sang/J-5398-2012 | 57224911284; 57203086704 | dandy813@hanmail.net; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 5 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0 | 2025-07-30 | 0 | 0 | INFLAMMATORY-BOWEL-DISEASE; NATURAL-HISTORY; EPIDEMIOLOGY | Age of Onset; Aged; Colitis, Ulcerative; Disease Progression; Humans; Middle Aged; corticosteroid; mercaptopurine; tumor necrosis factor inhibitor; all cause mortality; cancer growth; cancer mortality; cancer risk; clinical feature; colon resection; colorectal cancer; comorbidity; disease activity; disease duration; drug use; Editorial; follow up; human; Korea; laboratory test; lymphoproliferative disease; malignant neoplasm; myeloproliferative disorder; risk assessment; ulcerative colitis; aged; disease exacerbation; middle aged; onset age; ulcerative colitis | English | 2021 | 2021-09 | 10.5009/gnl210403 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Editorial Material | Journal of Korean Medical Science (JKMS): influential flagship medical journal in the Republic of Korea | Yoo, Jin-Hong; Kim, Jong-Min; Hong, Kyung Pyo; Lee, Jongmin; Hong, Sung-Tae | Journal Korean Med Sci, Seongnam, South Korea; Catholic Univ Korea, Div Infect Dis, Dept Internal Med, Coll Med, Seoul, South Korea; Bucheon St Marys Hosp, Div Infect Dis, Dept Internal Med, Bucheon, South Korea; Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Neurol, Seongnam, South Korea; Sungkyunkwan Univ, Dept Med, Sch Med, Seoul, South Korea; Korean Acad Med Sci, Int Affairs, Seongnam, South Korea; Kyungpook Natl Univ Hosp, Dept Radiol, Daegu, South Korea; Seoul Natl Univ, Coll Med, Dept Trop Med & Parasitol, Seoul, South Korea | Hong, Sung-Tae/J-5723-2012; Lee, Jongmin/AAR-6361-2020; Kim, Jong-Min/J-5435-2012; Yoo, Jin-Hong/HSF-2796-2023 | 7402295435; 55784601300; 58703788100; 55689919700; 7405767067 | hst@snu.ac.kr; | HONG KONG MEDICAL JOURNAL | HONG KONG MED J | 1024-2708 | 27 | 4 | SCIE | MEDICINE, GENERAL & INTERNAL | 2021 | 3.125 | 46.8 | 0.36 | 2025-07-30 | 0 | 1 | Humans; Publishing; Republic of Korea; adverse event; coronavirus disease 2019; Editorial; epidemic; infectious agent; medical literature; medicine; nonhuman; toxicity; human; publishing; South Korea | English | 2021 | 2021-08 | 10.12809/hkmj215119 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||||
| ○ | ○ | Article | Long-term Outcomes of Undifferentiated-Type Early Gastric Cancer with Positive Horizontal Margins after Endoscopic Resection | Background/Aims: This study examined the long-term outcomes of undifferentiated-type early gastric cancer (UD EGC) with positive horizontal margins (HMs) after endoscopic resection (ER) and compared them between additional surgery and nonsurgical management. Methods: From 2005 to 2015, a total of 1,124 patients with UD EGC underwent ER at 18 tertiary hospitals in Korea. Of them, 92 patients with positive HMs as the only noncurative factor (n=25) or with both positive HMs and tumor size >2 cm (n=67) were included. These patients underwent additional surgery (n=40), underwent additional endoscopic treatment (n=6), or were followed up without further treatment (n=46). Results: No lymph node (LN) metastasis was found in patients who underwent additional surgery. During a median follow-up of 57.7 months (interquartile range, 27.6 to 68.8 months), no LN or distant metastases or gastric cancer-related deaths occurred in the overall cohort. At baseline, the residual cancer rate was 57.8% (26/45) after additional surgery or ER. The 5-year local recurrence rate was 33.6% among patients who were followed up without additional treatment. The 5-year overall survival rates were 95.0% and 87.8% after additional surgery and nonsurgical management (endoscopic treatment or close follow-up), respectively (log-rank p=0.224). In the multivariate Cox regression analysis, nonsurgical management was not associated with an increased risk of mortality. Conclusions: UD EGC with positive HMs after ER may have favorable long-term outcomes and a very low risk of LN metastasis. Nonsurgical management may be suggested as an alternative, particularly for patients with old age or chronic illness. (Gut Liver 2021;15:723-731) | Yang, Hyo-Joon; Lee, Wan-Sik; Lee, Bong Eun; Ahn, Ji Yong; Jang, Jae-Young; Lim, Joo Hyun; Nam, Su Youn; Kim, Jie-Hyun; Min, Byung-Hoon; Joo, Moon Kyung; Park, Jae Myung; Shin, Woon Geon; Lee, Hang Lak; Gweon, Tae-Geun; Park, Moo In; Choi, Jeongmin; Tae, Chung Hyun; Kim, Young-Il; Choi, Il Ju | Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Internal Med,Div Gastroenterol, Seoul, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Gastrointestinal Canc Ctr, Seoul, South Korea; Chonnam Natl Univ, Med Sch, Dept Internal Med, Gwangju, South Korea; Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Div Gastroenterol,Dept Internal Med, Seoul, South Korea; Kyung Hee Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ Hosp, Healthcare Syst Gangnam Ctr, Inst Healthcare Res, Dept Internal Med, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Gastroenterol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Yonsei Univ, Gangnam Severance Hosp, Coll Med, Div Gastroenterol,Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul, South Korea; Korea Univ, Guro Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Hallym Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Internal Med, Div Gastroenterol, Seoul, South Korea; Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Div Gastroenterol,Dept Internal Med, Incheon, South Korea; Kosin Univ, Coll Med, Dept Internal Med, Busan, South Korea; Inje Univ, Sanggye Paik Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Ewha Womans Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Natl Canc Ctr, Ctr Gastr Canc, Goyang, South Korea | ; Kim, Jie-Hyun/Q-9061-2019; Park, Jae Myung/AGK-6655-2022; Kim, Seong Cheol/ABD-1493-2022; Ahn, Ji Yong/AGO-1695-2022; Lee, In/J-9324-2013; Kim, Yuriy/ABD-7016-2020 | 57188930761; 57208140974; 36461131900; 36809017800; 57215881098; 55774506200; 55617028500; 49461401400; 7202932034; 35313509000; 8548758100; 13606883400; 7501478057; 55365094900; 8666034000; 55646404000; 35211966400; 57203809495; 7401471464 | jadelook@hanmail.net;bongsul@daum.net; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 5 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0.54 | 2025-07-30 | 9 | 9 | Stomach neoplasms; Undifferentiated-type histology; Endoscopic mucosal resec-tion; Margins of excision; Lymphatic metastasis | LYMPH-NODE METASTASIS; SUBMUCOSAL DISSECTION; LATERAL MARGIN; CLINICAL-OUTCOMES; RISK-FACTORS | Endoscopic mucosal resection; Lymphatic metastasis; Margins of excision; Stomach neoplasms; Undifferentiated-type histology | Endoscopic Mucosal Resection; Gastrectomy; Humans; Margins of Excision; Neoplasm Recurrence, Local; Republic of Korea; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; adult; aged; anaplastic carcinoma; Article; cancer mortality; cancer patient; cancer recurrence; cohort analysis; conservative treatment; controlled study; distant metastasis; early cancer; endoscopic surgery; female; follow up; human; log rank test; lymph node metastasis; major clinical study; male; mortality risk; overall survival; proportional hazards model; retrospective study; South Korea; South Korean; stomach cancer; surgical margin; survival rate; tertiary care center; tumor volume; endoscopic mucosal resection; gastrectomy; stomach tumor; surgical margin; treatment outcome; tumor recurrence | English | 2021 | 2021-09 | 10.5009/gnl20291 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment | Background/Aims: Recent data indicate the presence of liver enzyme abnormalities in patients with coronavirus disease 2019 (COVID-19). We aimed to evaluate the clinical features and treatment outcomes of COVID-19 patients with abnormal liver enzymes. Methods: We performed a retrospective, multicenter study of 874 COVID-19 patients admitted to five tertiary hospitals from February 20 to April 14, 2020. Data on clinical features, laboratory parameters, medications, and treatment outcomes were collected until April 30, 2020, and compared between patients with normal and abnormal aminotransferases. Results: Abnormal aminotransferase levels were observed in 362 patients (41.1%), of which 94 out of 130 (72.3%) and 268 out of 744 (36.0%) belonged to the severe and non-severe COVID-19 categories, respectively. The odds ratios (95% confidence interval) for male patients, patients with a higher body mass index, patients with severe COVID-19 status, and patients with lower platelet counts were 1.500 (1.029 to 2.184, p=0.035), 1.097 (1.012 to 1.189, p=0.024), 2.377 (1.458 to 3.875, p=0.001), and 0.995 (0.993 to 0.998, p>0.001), respectively, indicating an independent association of these variables with elevated aminotransferase levels. Lopinavir/ ritonavir and antibiotic use increased the odds ratio of abnormal aminotransferase levels after admission (1.832 and 2.646, respectively, both p<0.05). The median time to release from quarantine was longer (22 days vs 26 days, p=0.001) and the mortality rate was higher (13.0% vs 2.9%, p<0.001) in patients with abnormal aminotransferase levels. Conclusions: Abnormal aminotransferase levels are common in COVID-19 patients and are associated with poor clinical outcomes. Multivariate analysis of patients with normal aminotransferase levels on admission showed that the use of lopinavir/ritonavir and antibiotics was associated with abnormal aminotransferase levels; thus, careful monitoring is needed. | Song, Jeong Eun; Kang, Min Kyu; Lee, Yu Rim; Lee, Chang Hyeong; Park, Jung Gil; Kweon, Young Oh; Tak, Won Young; Park, Soo Young; Jang, Se Young; Hwang, Jae Seok; Jang, Byoung Kuk; Jang, Won Young; Suh, Jeong Ill; Chung, Woo Jin; Kim, Byung Seok | Daegu Catholic Univ, Dept Internal Med, Sch Med, Daegu, South Korea; Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea; Dongguk Univ, Dept Internal Med, Coll Med, Gyeongju, South Korea | Kim, Seul Kee/A-6076-2015; Kang, Min/U-8050-2018; Kim, Jin Hyoung/AAE-8050-2019; Park, Jung/AAK-5167-2020; song, jeong/P-9106-2015 | 57189097150; 59142854300; 57194094753; 55784781600; 57216816399; 7004694832; 7004074582; 57191674344; 57202881977; 57205851488; 58849853600; 57218289218; 7201515001; 55741230500; 55974276800 | chung50@dsmc.or.kr;kbs9225@cu.ac.kr; | GUT AND LIVER | GUT LIVER | 1976-2283 | 2005-1212 | 15 | 4 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2021 | 4.321 | 46.8 | 0.38 | 2025-07-30 | 4 | 6 | SARS-CoV-2; COVID-19; Aminotransferase; Prognosis; Lopinavir-ritonavir | CORONAVIRUS DISEASE 2019 | Aminotransferase; COVID-19; Lopinavir-ritonavir; Prognosis; SARS-CoV-2 | Aged; COVID-19; Female; Humans; Liver; Liver Diseases; Male; Middle Aged; Prognosis; Retrospective Studies; Transaminases; aminotransferase; antibiotic agent; lopinavir plus ritonavir; aminotransferase; adult; aged; Article; body mass; clinical feature; coronavirus disease 2019; disease association; disease severity; drug use; female; hospital admission; human; liver dysfunction; major clinical study; male; mortality rate; platelet count; prognosis; quarantine; retrospective study; risk factor; tertiary care center; clinical trial; complication; enzymology; liver; liver disease; middle aged; multicenter study; prognosis; virology | English | 2021 | 2021-07 | 10.5009/gnl20267 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: